Elena Gonzalez-Gugel
Overview
Explore the profile of Elena Gonzalez-Gugel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farkas A, Youssef D, Tran M, Balan S, Newman J, Audenet F, et al.
bioRxiv
. 2024 May;
PMID: 38746459
NK cells are innate lymphocytes critical for surveillance of viruses and tumors, however the mechanisms underlying NK cell dysfunction in cancer are incompletely understood. We assessed the effector function of...
2.
Ni L, Khan A, Long A, Gao L, Toms N, Gonzalez-Gugel E, et al.
Clin Pharmacol Ther
. 2023 Apr;
114(1):77-87.
PMID: 37087634
Model-informed drug development (MIDD) is a process that integrates drug exposure-based, biological, and statistical models to enhance the benefit-risk balance in drug development. The US Food and Drug Administration (FDA)...
3.
Parikh A, Gonzalez-Gugel E, Smolyakova N, Jen M, Toms N, Lin Y, et al.
Oncologist
. 2022 May;
27(5):371-379.
PMID: 35522557
Background: Cetuximab 500 mg/m2 biweekly (Q2W) plus chemotherapy is commonly used and recommended by NCCN guidelines. This meta-analysis compares efficacy and safety between Q2W versus weekly (Q1W) cetuximab dosing. Methods:...
4.
Llovet J, Singal A, Villanueva A, Finn R, Kudo M, Galle P, et al.
Clin Cancer Res
. 2022 Mar;
28(11):2297-2305.
PMID: 35247922
Purpose: Ramucirumab is an effective treatment for patients with advanced hepatocellular carcinoma (aHCC) and baseline alpha-fetoprotein (AFP) ≥400 ng/mL. We aimed to identify prognostic and predictive factors of response to...
5.
Yi Y, Jian J, Gonzalez-Gugel E, Shi Y, Tian Q, Fu W, et al.
EBioMedicine
. 2018 Feb;
29:78-91.
PMID: 29472103
p204, a murine member of an interferon-inducible p200 family, was reported to recognize intracellular viral and bacterial DNAs, however, its role in the innate immunity in vivo remains unknown due...
6.
Gonzalez-Gugel E, Saxena M, Bhardwaj N
Cancer Immunol Immunother
. 2016 Jun;
65(10):1261-8.
PMID: 27344341
A recent report from the Center for Disease Control identified melanoma as being among the highest causes of cancer-related mortalities in the USA. While interventions such as checkpoint blockade have...
7.
Three TNFR-binding domains of PGRN act independently in inhibition of TNF-alpha binding and activity
Tian Q, Zhao Y, Mundra J, Gonzalez-Gugel E, Jian J, Uddin S, et al.
Front Biosci (Landmark Ed)
. 2014 Jun;
19(7):1176-85.
PMID: 24896343
PGRN was previously reported to bind to TNF receptors (TNFR) and is therapeutic against inflammatory arthritis. Here we present further evidences demonstrating the PGRN inhibition of TNF-alpha binding and activity,...
8.
Uddin S, Mundra J, Jian J, Tian Q, Gonzalez-Gugel E, Richbourgh B, et al.
Immunol Cell Biol
. 2014 Feb;
92(4):299-300.
PMID: 24518982
No abstract available.
9.
Jian J, Zhao S, Tian Q, Gonzalez-Gugel E, Mundra J, Uddin S, et al.
FEBS Lett
. 2013 Sep;
587(21):3428-36.
PMID: 24070898
We previously reported that PGRN directly bound to TNF receptors (TNFR) in vitro and in chondrocytes (Tang, et al., Science, 2011). Here we report that PGRN also associated with TNFR...
10.
Gonzalez-Gugel E, Villa-Morales M, Santos J, Bueno M, Malumbres M, Rodriguez-Pinilla S, et al.
Carcinogenesis
. 2013 Jan;
34(4):902-8.
PMID: 23288923
Inappropriate activation of the GLI/hedgehog (GLI/Hh) signalling occurs in several human cancers, including haematological neoplasms. However, little is known about its relevance in precursor T-cell lymphoblastic lymphomas (T-LBL) development. Moreover,...